BioLineRx Ltd. (NASDAQ: BLRX)

BioLineRx Ltd. is a biopharmaceutical company focused on discovering and developing life changing therapies in oncology and rare diseases.

The company was founded in 2003 by leading institutions in the Israeli life sciences sector.

Its principal executive offices are located at 2 HaMa’ayan Street Modi’in 7177871 Israel.

BioLineRx Ltd. completed its initial public offering in Israel in February 2007 and its ordinary shares are traded on the TASE under the symbol BLRX.

In July 2011 the company listed its ADSs on Nasdaq where they trade under the symbol BLRX.

The firm operates through a wholly owned subsidiary BioLineRx USA Inc. incorporated in Delaware and a partially owned subsidiary Tetragon which holds the GLIX1 program.

BioLineRx Ltd. concentrates its research and development efforts on candidates such as motixafortide APHEXDA GLIX1 and the legacy product BL 5010.

The company seeks to in license additional assets in oncology and rare diseases to build a diversified pipeline that addresses significant unmet medical needs.

BioLineRx Ltd. generates revenue principally from upfront payments milestone payments and royalties received under its out licensing agreements.

In November 2024 the company out licensed the global rights other than in Asia to motixafortide for all indications except solid tumors to Ayrmid Pharma Ltd. for a ten million dollar upfront payment and potential sales milestones up to eighty seven million dollars.

In October 2023 BioLineRx Ltd. out licensed the rights to motixafortide for all indications in substantially all of Asia to Gloria for a fifteen million dollar upfront payment and potential sales milestones up to one hundred ninety seven million dollars.

The company also retains rights to develop motixafortide for solid tumor indications outside Asia and receives potential milestone and royalty income from those programs.

Under the collaboration with Hemispherian BioLineRx Ltd. holds a forty percent interest in Tetragon and is entitled to future milestone and royalty payments from the GLIX1 program.

Revenues are also derived from the sale of the legacy product BL 5010 which has been out licensed to Perrigo Company plc for over the counter indications in Europe Australia and selected other countries.

Additional income may arise from sublicensing arrangements and from the provision of transition services to partners.

The company maintains a lean cost structure following the shutdown of its independent commercialization activities in the United States which has reduced its annual cash burn rate.

BioLineRx Ltd. occupies a specialized niche in the biopharmaceutical industry as a developer of innovative therapies targeting high unmet medical needs in oncology and rare diseases.

The company competes with larger multinational pharmaceutical firms but differentiates itself through a disciplined in licensing strategy that emphasizes modest upfront payments and success based considerations.

Its product candidates benefit from orphan drug designations which provide market exclusivity and potential tax credits.

Motixafortide APHEXDA has received three orphan drug designations from the FDA for hematopoietic stem cell mobilization acute myeloid leukemia and pancreatic cancer and similar designations from the EMA.

GLIX1 has received orphan drug designation from both the FDA and the EMA for glioblastoma underscoring the substantial unmet need in that indication.

The firm leverages its expertise in asset scouting and validation to select candidates with a high probability of therapeutic and commercial success.

BioLineRx Ltd. seeks to build value by advancing development programs that can be supported by royalties and milestones from existing partnerships.

The company believes its deep scientific knowledge prudent financial management and strategic focus position it uniquely to bring forward novel therapies that can redefine standards of care.

BioLineRx Ltd. serves a diverse customer base that includes patients receiving treatment for cancer and rare diseases.

Healthcare providers such as hospitals oncology clinics and transplantation centers are key users of its product candidates.

The company partners with pharmaceutical firms that handle commercialization and distribution in specific territories.

Notable partners include Ayrmid Pharma Ltd. which commercializes motixafortide APHEXDA globally excluding Asia and Gloria which handles the Asian territory.

Perrigo Company plc holds the license for the over the counter product BL 5010 in Europe Australia and selected other countries.

Research institutions and clinical trial sponsors also form an important part of the customer base.

Examples include Columbia University which sponsors an investigator initiated Phase 2b trial of motixafortide in pancreatic cancer and St. Jude Children’s Research Hospital which conducts studies on hematopoietic stem cell mobilization for sickle cell disease.

Additionally the company works with academic collaborators such as Washington University School of Medicine in St. Louis and Regeneron on various development programs.

These relationships enable BioLineRx Ltd. to access clinical expertise patient populations and regulatory support while maintaining focus on early stage development and partner driven commercialization.